Relmada Therapeutics, Inc. (RLMD)
Stock Price:
$30.93 USD
-0.23 (-0.74%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
495.62M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-29.99M |
| Shares Out |
16.02M |
| EPS (ttm) |
-2.22 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$30.93 |
| Previous Close |
$31.16 |
| Change ($) |
-0.23 |
| Change (%) |
-0.74% |
| Day's Open |
31.24 |
| Day's Range |
30.30 - 32.26 |
| Day's Volume |
185,683 |
| 52-Week Range |
28.40 - 54.00 |
More Stats
| Market Cap |
495.62M |
| Enterprise Value |
361.53M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.02M |
| Float |
14.65M |
| EPS (basic) |
-2.22 |
| EPS (diluted) |
-2.22 |
| FCF / Share |
-0.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.77M |
| Short Ratio |
15.83 |
| Short % of Float |
12.10% |
| Beta |
0.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.84 |
| Revenue |
n/a |
| Operating Income |
-31.00M |
| Net Income |
-29.99M |
| Free Cash Flow |
-14.79M |
| Net Cash |
134.09M |
| Net Cash / Share |
8.37 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-158.57% |
| ROE |
-25.63% |
| ROIC |
-40.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$63.17*
(104.24% upside)
Low
40.0
Current: $30.93
High
75.0
Target: 63.17
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -12.73 | -6.92 | -7.22 | -16.22 | -17.10 |
| Net Income | -17.32 | -8.96 | -6.29 | -2.97 | -20.80 |
| Shares Outstanding | 6.31 | 3.14 | 3.02 | 2.90 | 2.49 |
| Earnings Per Share | -2.74 | -2.86 | -2.08 | -1.04 | -8.36 |
| Operating Cash Flow | -10.50 | -6.00 | -6.47 | -13.14 | -16.23 |
| Capital Expenditures | - | -0.01 | -0.05 | -0.56 | -0.02 |
| Free Cash Flow | -10.50 | -6.01 | -6.52 | -13.71 | -16.25 |
| Cash & Equivalents | 9.22 | 2.24 | 1.71 | 8.50 | 22.47 |
| Total Debt | 0.36 | 2.94 | 0.28 | 0.27 | 0.26 |
| Net Cash / Debt | 8.85 | -0.70 | 1.43 | 8.23 | 22.21 |
| Assets | 10.22 | 3.05 | 2.84 | 10.24 | 24.39 |
| Liabilities | 2.61 | 8.56 | 1.38 | 3.20 | 15.58 |
| Book Value | 7.61 | -5.51 | 1.46 | 7.04 | 8.81 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Relmada Therapeutics, Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
Sergio Traversa |
Stock Information
| Ticker Symbol |
RLMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: RLMD |
Description
Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.